03/07/2003Copyright  2003 Georgetown University1 Compliance Programs in Academic Medical Centers Kenneth L. Dretchen, PhD Director of Regulatory Affair.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
VCOM Conflict of Interest Policy Overview of Financial Conflict of Interest Related to Research December 4, 2013.
Tips to a Successful Monitoring Visit
1 The HIPAA Privacy Rule and Research This presentation will probably involve audience discussion, which will create action items. Use PowerPoint to keep.
TM The HIPAA Privacy Rule: Safeguarding Health Information in Research and Public Health Practice Centers for Disease Control and Prevention Beverly A.
Health Insurance Portability Accountability Act of 1996 HIPAA for Researchers: IRB Related Issues HSC USC IRB.
VETERANS BENEFITS ADMINISTRATION AVECO July 14 – 18, 2014 Centralized Certification.
CRC Protocol Documents Protocol Submissions Amendments Publications Study Closure.
Greg E. Manship, M.Div., MT(ASCP), CIM, CIP IRB Coordinator, University of Indianapolis Co-Vice Chair, Community Health Network IRB.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
National Cancer Institute (NCI) Central Institutional Review Board (CIRB) Research Studies UCSF HRPP Submission Process Overview Tuesday, December.
CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Office of Research Integrity Office of Research Integrity Orientation Session November 8, 2012 ECSS
O FFICE OF S CIENCE & R ESEARCH OSR O FFICE OF S CIENCE & R ESEARCH OSR Welcome to the Research Navigator Institutional Biosafety Committee (IBC) Creation.
Overview of Good Clinical Practices (GCPs)
Federalwide Assurance Presentation for IRB Members.
O FFICE OF S CIENCE & R ESEARCH OSR O FFICE OF S CIENCE & R ESEARCH OSR Welcome to the Research Navigator Institutional Biosafety Committee (IBC) Learning.
Educational Research and the VCOM Institutional Review Board
Using Technology to Strengthen Human Subject Protections Patricia Scannell Director, IRB Washington University School of Medicine.
O FFICE OF S CIENCE & R ESEARCH OSR O FFICE OF S CIENCE & R ESEARCH OSR Welcome to the Research Navigator Institutional Biosafety Committee (IBC) Learning.
1.02 Advanced Compliance Strategies for Academic Medical Centers Kenneth L. Dretchen and Shelia Zimmet Georgetown University Medical Center.
Pre-Award Issues Related to Human Research and Animal Use March 15, 2013.
Primary Care and Community Outreach Research VCOM Institutional Review Board Jim Mahaney, PhD Associate Dean for Biomedical Affairs, Virginia Campus Past.
Investigational New Drug Application (IND)
1 The Auditor’s Perspective Division of Sponsored Research Research Administration Training Series Presented by: Joe Cannella Audit Manager,
O FFICE OF S CIENCE & R ESEARCH OSR O FFICE OF S CIENCE & R ESEARCH OSR Welcome to Click Institutional Biosafety Committee (IBC) Learning Module.
Responsible Conduct of Research (RCR) What is RCR? New Requirements for RCR Who Does it Affect? When? Data Management What is the Institutional Plan? What.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Research Compliance: An Overview of the Players and Issues Involved in Emory’s Research Compliance Programs.
O FFICE OF S CIENCE & R ESEARCH OSR O FFICE OF S CIENCE & R ESEARCH OSR Welcome to the Research Navigator Institutional Biosafety Committee (IBC) Learning.
H I P A A T R A I N I N G Self Directed Module 7 Research Disclosures For Data Custodians START Click to begin…
The Institutional Review Board: A Community College Toolkit Dr. Geri J Anderson.
Investigators’ Responsibilities in Conducting Human Subjects Research Dept. of Regulatory Affairs April 18, 2012.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Marian University is sponsored by the Sisters of St. Francis, Oldenburg. Human Subjects Research and the Marian University Institutional Review Board (IRB)
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
Integrating a Federated Healthcare Data Query Platform With Electronic IRB Information Systems Shan He IPHIE 2010.
1 April 21 – 23, 2004 Baltimore, Maryland John Arnaldi, Ph.D. Coordinator of Education USF Research Compliance Barry Bercu, M.D. Chair, USF Biomedical.
Yadvindera (Bobby) Bains MD Director of Radiation Oncology, Laredo Medical Center Adjunct Associate Professor, Dept of Radiation Oncology, University of.
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
FDA: 3/21/05 Computerized Adverse Event Reporting (CAER) Office of Regulatory Affairs Georgetown University Medical Center Washington, DC Sorell L. Schwartz,
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
FIRE1000S - Self-Paced FIREBIRD Training Training on the Federal Investigator Registry of Biomedical Informatics Research Data (FIREBIRD) for Clinical.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
The Role and Responsibilities of the Clinical Research Coordinator
Conditional IRB Approval
Introduction to the Human Research Protections Office (HRPO)
The Information Professional’s Role in Product Safety
New Faculty Orientation Office of the Vice President for Research
Clinical Engineering Lecture (3).
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
For investigators planning to conduct human participant research
The HIPAA Privacy Rule and Research
eResearch at Emory Phase I: eIRB
IRB Harmonization 2016 Review
Research with Human Subjects
Presentation transcript:

03/07/2003Copyright  2003 Georgetown University1 Compliance Programs in Academic Medical Centers Kenneth L. Dretchen, PhD Director of Regulatory Affair Chair, Department of Pharmacology Sheila Cohen Zimmet, RN, JD Director, Research Assurance and Compliance Special Guest: Kolaleh Eskandanian, PhD, MBA Program Manager Georgetown University

03/07/2003Copyright  2003 Georgetown University2 Regulatory Affairs Oversight (1)Human Subject Protection (2)HIPAA Privacy (3)Animal Care and Use (4)Conflict of Interest (5)Research Integrity (6)Institutional Biosafety (7)Radiation Safety

03/07/2003Copyright  2003 Georgetown University3 Research Compliance  Institutional Review Boards  staffing/resource  Membership  Quality and Timeliness of Review  Informed Consent Documents  CIRB ( Joint initiative between NCI and OHRP  Institutional Biosafety Committee  Gene Therapy/Recombinant DNA – Office of Biotechnology Activities ( ) (www4.od.nih.gov/oba/)  Select agents ( (see the interim final rule on the Possession, Use and Transfer of Select Agents and Toxins – 42CFR Part 73)

03/07/2003Copyright  2003 Georgetown University4 Human Subject Protection in Research Training Alternatives Certification that one has completed training in human subject protection in research is required of all Georgetown University faculty, investigators, study coordinators and other individuals directly involved in human subject research. An individual may complete this training, which should be updated annually, by: 1 - taking the on-line NIH course ( This on-line programhttp://cme.nci.nih.gov prints a completion certificate at the end of the program. A copy of the certificate needs to be forwarded to Dorothea Hudley, Grants Assistant, Research and Technology Development Services, 177 Building D, so she can record in her GU database that you have completed the training. This course may be used to comply with either the Basic or the Refresher training required by Georgetown. or

03/07/2003Copyright  2003 Georgetown University5 Human Subject Protection in Research Training Alternatives [continued] 2 – attending the Basic (for first-time traineees) or Refresher training session, or viewing the applicable videotape of these PricewaterhouseCoopers training sessions; the videotapes Are kept on the GCRC (General Clinical Research Center), 7 Main Hospital. To view either of these tapes, phone the GCRC Nursing Station, ext , to schedule a convenient time for viewing in a room on their unit. After completion of the tape, you complete a form that provides information for the GU training database. or 3 – viewing the OHRP Investigator 101 Training Course (PRIM&R copyright 2001) available on CD-ROM. To borrow a copy of the CD-ROM and User’s Manual, please contact either the Biomedical Institutional Review Board (IRB) office at ext or ext , or the Social-Behavioral IRB office at ext You will be asked to complete a training course sheet when you return the CD-ROM and manual to the applicable IRB office. In any case, contact Dorothea Hudley (ext , or georgetown.edu) when you need to request a copy of your Georgetown certificate of completion.

03/07/2003Copyright  2003 Georgetown University6 Research Compliance [Continued]  HIPAA and Research  role of IRB  tissue banks—unspecified future use  Authorization for Disclosure/Consent  Resources  HHS/OCR Guidance (  American Council on Education ( “Impact of the HIPAA Privacy Rule on Academic Research”)

03/07/2003Copyright  2003 Georgetown University7 Conflict of Interest  Financial Conflicts of Interest Policy  disclosure forms  Conflict of Interest Information Resources available on the web

03/07/2003Copyright  2003 Georgetown University8 Research Compliance [Continued]  Clinical Trials Office  Grants Management  University Counsel  Internal Audit

03/07/2003Copyright  2003 Georgetown University9 Professional Associations  AAMC – Association of American Medical Colleges   exculpatory language  COGR – Council on Governmental Relations (association of research universities) Army Grants compensation for injury publication of research results -- government clearance/confer and consult

03/07/2003Copyright  2003 Georgetown University10 Examples of Exculpatory Language  By agreeing to this use, you should understand that you will give up all claim to personal benefit from commercial or other use of these substances.  I voluntarily and freely donate any and all blood, urine, and tissue samples to the U.S. Government and hereby relinquish all rights, title, and interest to said items.  By consent to participate in this research, I give up any property rights I may have in bodily fluids or tissue samples obtained in the course of the research.  I waive any possibility of compensation for injuries that I may receive as a result of participation in this research.

03/07/2003Copyright  2003 Georgetown University11 Examples of Acceptable Language  Tissue obtained from you in this research may be used to establish a cell line that could be patented and licensed. There are no plans to provide financial compensation to you should this occur.  By consenting to participate, you authorize the use of your bodily fluids and tissue samples for the research described above.  This hospital is not able to offer financial compensation nor to absorb the costs of medical treatment should you be injured as a result of participating in this research.  This hospital makes no commitment to provide free medical care or payment for any unfavorable outcomes resulting from participation in this research. Medical services will be offered at the usual charge.

03/07/2003Copyright  2003 Georgetown University12 Re:US Army Medical Research & Military Command (USAMRMC) Change in reimbursement restrictions for research related injury or illness Ask your grant/contract officer at Fort Detrick to contact Robert Charles about the changes in reimbursment restrictions:

03/07/2003Copyright  2003 Georgetown University13 Computerized Adverse Event Reporting (CAER) Authors: Sorell L. Schwartz, PhD Professor Emeritus of Pharmacology Department of Pharmacology, Georgetown University Medical Center Chairman, IRB Subcommittee on Adverse Events Office of Regulatory Affairs, Georgetown University Kolaleh Eskandanian, PhD, MBA CAER, Program Manager Office of Regulatory Affairs, Georgetown University

03/07/2003Copyright  2003 Georgetown University14 CAER Background  The Computerized Adverse Event Reporting (CAER) project was created to require the establishment of processes for the reporting, analysis, and prevention of Serious Adverse Events (SAEs), and the implementation of a system that includes conducting analysis when an adverse event occurs, and developing strategies to reduce the risk of similar incidents occurring in the future. The requirements for CAER were gathered by interviewing various user groups including principal investigators, administrators, nurses, Georgetown University IRB reviewers and executive members, and the NIH Office of Biological Activities.

03/07/2003Copyright  2003 Georgetown University15 Business Case  Patient/Subject safety and compliance with regulatory requirements  Reporting of SAEs is an important component of the Data Safety Monitoring Plan (DSMP). The prompt review of SAEs is required to determine whether a study should be discontinued or whether additional patient care resources should be added.  Adverse event data volume is increasing steadily and the need for quick and easy access to trial data is becoming critical. CAER offers extensive features that expedite the management and reporting of adverse event data while maintaining regulatory compliance.  Central repository of adverse events  This will facilitate cross-trial analyses, searches for specific variables, and identification of trends.  CAER provides both “Ad Hoc” and “Pre-formatted” reports for the generation of in- depth queries and to permit analyses. For example, CAER database can be queried by type of adverse event, disease, phase of study, protocol, principal investigator, etc.  Controlled Vocabulary  CAER is integrated with MedDRA (Medical Dictionary for Regulatory Activities). This is essential for cross-trial analyses.

03/07/2003Copyright  2003 Georgetown University16 CAER Users  CAER will be used by all research initiatives that are under the oversight of GU IRB.  CAER has been designed with flexibility in mind. The system uses the personalization technology to tailor the interface for the use at a specific institution with specific needs.

03/07/2003Copyright  2003 Georgetown University17 Summary of CAER Features  Allows for the electronic submission of internal and external Serious Adverse Event (SAE)  Allows to create both a new report and a follow-up report  Allows for incremental saving  Validates data for completeness and consistency  Uses MedDRA as standard medical vocabulary  Allows for trend and root cause analyses

03/07/2003Copyright  2003 Georgetown University18 Built-in Messaging Component  Notifies the recipients (e.g., IRB, RSA, PI) of the availability of an AE report.  When a report is finished processing, the server sends a formatted mail message to the recipients, notifying that the AE report is available. The recipient can then view the report using the URL provided in the mail message  Sends reminders to the users, notifying them to complete the AE report form.  When an AE is submitted as ‘Initial’, the server sends a formatted mail message to the user every 7 days (or as specified), reminding them of completing the form.

03/07/2003Copyright  2003 Georgetown University19 User Access  Supports system administration tool for user profiling and defining user displays  Defines editing privileges depending on user type; grants or denies user access to different modules  Provides user access via the Internet using SSL  Access via GU NetID and Password  Supports concurrent user access

03/07/2003Copyright  2003 Georgetown University20 System Security  Development, Testing, and Production Servers compliant with 45CFR142 – security and electronic signature standards  Includes encrypted passwords, user lockout after a predefined number of unsuccessful logons  Sessions will be suspended after a specified period of inactivity and require password to be re-entered  Audit trail records user access to each data record and any modifications made  Version control tracks changes as required by GCP guidelines

03/07/2003Copyright  2003 Georgetown University21 Compliance with Standards  Controls medical vocabulary  Uses MedDRA terms for the coding of adverse events, allowing for consistent use of medical terminology  Is compliant with Section 508  Has the potential of using HL7 standards to submit pre- and post marketing SAE reports to the FDA (contingent upon FDA approval)

03/07/2003Copyright  2003 Georgetown University22